Clarendon Fund Managers | Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fundand joinedby LifeArc and UK Future Fund
post-template-default,single,single-post,postid-1934,single-format-standard,qode-listing-1.0.1,qode-social-login-1.0,qode-news-1.0,qode-quick-links-1.0,qode-restaurant-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,qode-content-sidebar-responsive,qode-theme-ver-12.1,qode-theme-bridge,bridge,wpb-js-composer js-comp-ver-5.4.2,vc_responsive

Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fundand joinedby LifeArc and UK Future Fund

Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fundand joinedby LifeArc and UK Future Fund

Congratulations to our portfolio company, Cumulus Neuroscience, on securing a £6m investment from industry specialists to help further accelerate the development of its central nervous system therapies.

Cumulus Neuroscience (Cumulus, The Company), formerly known as BrainWaveBank, announces a £6m financing round led by the Dementia Discovery Fund (DDF) joined by LifeArc, a medical research charity, and the UK Future Fund.

Cumulusis a globally leading innovator in providing “real-world” clinical trial data andAI-poweredinsights, to accelerate the development of life-changing CNS therapies.

The Company’s next-generation integrated biomarker platform is being co-developed with some of the world’s leading pharmaceutical companies. It will greatly improve the robustness of neuroscience clinical trials by allowing more objective and preciseassessment of drug candidates on ashortertimeline, witha view to industry-wide adoption as a gold standard for real-world measurement of disease progression and treatment response. At present there is no similar integrated solution available to companies focused on neuroscience drug development.

Cumulus Neuroscience’sintegrated solution is a state-of-the-artplatform capable of:

Capturing frequent, longitudinal measurements of brain activity synchronously with a comprehensive range of functional and symptomaticdomains outside of the clinic, and

Providing unparalleled insights, powered by AI techniques,to support clinical trial decision making and execution.

This integrated platform, built on both proprietary expertise and partnerships with proven leaders in their field,remotely captures large amounts of real-world lab-quality data. Across the time-course of a clinical trial, mobile device-based assessments and simultaneous brain activity recordings track the full spectrum of drug mechanisms, neurophysiological functions,and patient symptoms, all in a user’s home.

Cumulus Neuroscience has developed a first-in-class home usable EEG headset that can objectively probe neuronal integrity, network connectivity and the strategies the brain uses to compensate for neuronal damage. Uniquely, theseEEG signalsare synchronised with mobile device-based functional assessments of 4 neurofunctional domains: cognition, mood, language, and sleep. The platform provides secure cloud-based data storage and a machine learning architecture to safely analyse composite behavioural, physiological,and functional data.

Cumulus Neuroscience’s platform also provides cutting-edge AI-based data analysis allowing it to detect subtle but therapeutically relevantchanges in patients,to generate fast and meaningful insights and to provide the best and most cost-effective assessment of CNS treatment outcomes.

Cumulus Neuroscience drawson the support of its world-class Scientific and Technical Advisory Board and research partners to develop its cutting edge, integrated platform. Its research partners include a group of six of the leading pharmaceutical companies in CNS drug development.

Cumulus Neuroscience’s CEO Ronan Cunningham commented:“We are delighted that DDF and LifeArc share our mission, addressing theclear need for more effective tools to provide the critical clinical trial data and analysis needed to improve the successful delivery of new CNS therapies to patients. This funding will allow us to build on the ground-breaking advances we have made in remote, frequent monitoring of brain activity and cognitive function in the home, in partnership with leading developers of digital biomarkers. We believe our integrated next generation platform can improve the execution of clinical trials by yieldingsignificant time and cost savings, addingmeaningfulvalue to the next generation of CNS therapies.”

Ruth McKernan DDF venture partner and co-founder said: “Clinical trials indementia are difficult and the results have been largely disappointing, partly due to the limitations of clinical trial methodology. My colleagues in the DDF and a group of Pharma companies andI have spent over a year working together on how tomeasure disease progression and the effects of drugs better. The result is Cumulus Neuroscience,and we look forward to seeing how this enablingplatform technology can be used in dementia clinical studies in the coming years, including those being run by DDF portfolio companies. If the platform is successful, then patients will benefit from better drugs sooner.”

Melanie Lee Chief Executive Officer from LifeArc said “LifeArc is pleased to invest in Cumulus Neurosciences’ platform, which we believe has strong potential to accelerate the development of life-changing CNS therapies, addressing an area of significant unmet patient need. This investment aligns with LifeArc’s interest in the power of the combination of data, AI and devices in healhcare.”